^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

33P - Antitumor activity of TROP2 Antibody Drug Conjugate Datopotamab Deruxtecan in Chemotherapy-Resistant Breast Cancer Models

Published date:
05/07/2023
Excerpt:
We assessed the antitumor activity in a panel of breast cancer PDXs varying in TROP2 expression….In isogenic breast cancer cell lines, overexpression of TROP2 expression conferred in vitro antitumor activity of Dato-DXd